COL5A2 Antibody

1. Bladder cancer patients in COL5A2 low expression group were associated with better invasiveness (P < .0001), tumor grade (P=.001), T staging (P < .0001), N staging (P = .002), and a trend of better M staging (P = .053) than those in COL5A2 high expression group. These results indicated that COL5A2 might promote the progression of Bladder Cancer cells. PMID: 29517678
2. COL5A2(+/-) humans, although unlikely to present with frank classic Ehlers-Danlos syndrome, are likely to have fragile connective tissues with increased susceptibility to trauma and certain chronic pathologic conditions. PMID: 25987251
3. Col5a2 shows predictive potential in myocardial infarction , and in principle may represent a novel candidate marker for the identification and treatment of ischemic cardiovascular disease PMID: 23574622
4. Before but not after developing bronchiolitis obliterans, lung transplantation patients had antibodies to Col-V, alpha2(V). Pep5-8 to alpha1,2(V) and pep9-14 to alpha2(V)were immunodominant. PMID: 22132895
5. Mutations in the COL5A2 gene have been identified by DNA sequence analysis in 10 patients with spontaneous vertebral artery dissections. PMID: 11940702

Show More

Hide All

HGNC: 2210

OMIM: 120190

KEGG: hsa:1290

STRING: 9606.ENSP00000364000

UniGene: Hs.445827